Bryan R Luce
Biographic Data
| ID | 2046872 |
|---|---|
| NAME | Bryan R Luce |
| GIVEN NAMES | Bryan R |
| FAMILY NAME | Luce |
| SIGNATURE | LUCE B R |
| AFFILIATIONS | United States Congress |
| VERIFIED | No |
| TOTAL WORKS | 9 |
| TOTAL CITATIONS | 4 |
| WORKS AS AUTHOR | 9 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 1979 |
| LATEST PUBLICATION YEAR | 2015 |
| H-INDEX | 1 |
The Patient-centered Outcomes Research Institute’s Role in Advancing Methods for Patient-centered Outcomes Research
Currently, there is wide-spread recognition that much of health care is insufficiently grounded in evidence as to what works for whom under what circumstances. An important reason for this is that research efforts often do not compare alternative options of health care nor are they sufficiently focused on outcomes that matter to patients.1,2 In addition, the methods to conduct research designed to inform decision makers about what works for whom …
Bayesian Meta-Analyses for Comparative Effectiveness and Informing Coverage Decisions
BACKGROUND: Evidence-based medicine is increasingly expected in health care decision-making. The Centers for Medicare and Medicaid have initiated efforts to understand the applicability of Bayesian techniques for synthesizing evidence. As a case study, a Bayesian analysis of clinical trials of implantable cardioverter defibrillators was undertaken using patient-level data not typically available for analysis. PURPOSE: Conduct Bayesian meta-analys…
What Will It Take to Make Cost-Effectiveness Analysis Acceptable in the United States
Many believe cost-effectiveness analysis (CEA) to be an underused tool to assist healthcare decision-makers. Reasons given for its underuse have largely focused on unstandardized methods, potential for bias, lack of training particularly among potential consumers of studies, and lack of trust between sponsors and users of analyses. This commentary reflects on these and related issues, including legal and political constraints. It discounts many o…
Health Care CBA and CEA from 1991 to 1996
OBJECTIVES: This article updates, through 1996, a previously published bibliography of health-care cost-benefit and cost-effectiveness analysis, which described the literature from 1979 to 1990. METHODS: A systematic search of MEDLARS databases was conducted for all articles falling under the medical subject headings "cost-benefit analysis" (which includes cost-effectiveness analysis) and "costs and cost analysis," as well as any article with the…
Managed care pharmacy, socioeconomic assessments and drug adoption decisions
A telephone survey of a representative national sample of 51 large managed care organizations in the U.S. (> 50,000 enrollees) was undertaken (1) to understand the role of socioeconomic assessments on drug adoption decisions; (2) to determine the sources of these assessments and the reliance of managed care pharmacy on each; and (3) to determine the resources for internally versus externally performed drug assessments. Socioeconomic assessments (…
Health Care CBA/CEA
Cost-benefit (CBA) and cost-effectiveness analyses (CEA) are methods that enumerate the costs and consequences associated with health-related technologies, services, and programs. This article examines the trends in published CBA and CEA of personal health services from 1979 through 1990. It is based on a bibliography that was compiled to help address the immense need for information on the variation and effectiveness of medical practices, partic…
Cost-Benefit and Cost-Effectiveness Analysis in Health Care
Cost-Benefit and Cost-Effectiveness Analysis in Health Care
Hospital Cost Containment Programs
Managed care pharmacy, socioeconomic assessments and drug adoption decisions
A telephone survey of a representative national sample of 51 large managed care organizations in the U.S. (> 50,000 enrollees) was undertaken (1) to understand the role of socioeconomic assessments on drug adoption decisions; (2) to determine the sources of these assessments and the reliance of managed care pharmacy on each; and (3) to determine the resources for internally versus externally performed drug assessments. Socioeconomic assessments (…
Hospital Cost Containment Programs
Cost-Benefit and Cost-Effectiveness Analysis in Health Care
Cost-Benefit and Cost-Effectiveness Analysis in Health Care
Health Care CBA/CEA
Cost-benefit (CBA) and cost-effectiveness analyses (CEA) are methods that enumerate the costs and consequences associated with health-related technologies, services, and programs. This article examines the trends in published CBA and CEA of personal health services from 1979 through 1990. It is based on a bibliography that was compiled to help address the immense need for information on the variation and effectiveness of medical practices, partic…
Managed care pharmacy, socioeconomic assessments and drug adoption decisions
A telephone survey of a representative national sample of 51 large managed care organizations in the U.S. (> 50,000 enrollees) was undertaken (1) to understand the role of socioeconomic assessments on drug adoption decisions; (2) to determine the sources of these assessments and the reliance of managed care pharmacy on each; and (3) to determine the resources for internally versus externally performed drug assessments. Socioeconomic assessments (…
Health Care CBA and CEA from 1991 to 1996
OBJECTIVES: This article updates, through 1996, a previously published bibliography of health-care cost-benefit and cost-effectiveness analysis, which described the literature from 1979 to 1990. METHODS: A systematic search of MEDLARS databases was conducted for all articles falling under the medical subject headings "cost-benefit analysis" (which includes cost-effectiveness analysis) and "costs and cost analysis," as well as any article with the…
What Will It Take to Make Cost-Effectiveness Analysis Acceptable in the United States
Many believe cost-effectiveness analysis (CEA) to be an underused tool to assist healthcare decision-makers. Reasons given for its underuse have largely focused on unstandardized methods, potential for bias, lack of training particularly among potential consumers of studies, and lack of trust between sponsors and users of analyses. This commentary reflects on these and related issues, including legal and political constraints. It discounts many o…
Bayesian Meta-Analyses for Comparative Effectiveness and Informing Coverage Decisions
BACKGROUND: Evidence-based medicine is increasingly expected in health care decision-making. The Centers for Medicare and Medicaid have initiated efforts to understand the applicability of Bayesian techniques for synthesizing evidence. As a case study, a Bayesian analysis of clinical trials of implantable cardioverter defibrillators was undertaken using patient-level data not typically available for analysis. PURPOSE: Conduct Bayesian meta-analys…
The Patient-centered Outcomes Research Institute’s Role in Advancing Methods for Patient-centered Outcomes Research
Currently, there is wide-spread recognition that much of health care is insufficiently grounded in evidence as to what works for whom under what circumstances. An important reason for this is that research efforts often do not compare alternative options of health care nor are they sufficiently focused on outcomes that matter to patients.1,2 In addition, the methods to conduct research designed to inform decision makers about what works for whom …
Health Systems, Economic Evaluations, Quality of Life (7 works) · Health care (6 works) · Political science (6 works) · Medicine (5 works) · Business (4 works) · Computer Science (4 works) · Healthcare cost, quality, practices (4 works) · Cost analysis (3 works) · Cost–benefit analysis (3 works) · Economics (3 works)